參考文獻
王瑩(2017)．Mepolizumab在嗜酸性白血球表現型的嚴重氣喘治療．台灣氣喘衛教學會會刊，44，3-8。
林慶雄(2013)．嚴重氣喘病人的標靶治療．台灣氣喘衛教學會會刊，33，4-5。
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., ... & Pavord, I. D. (2014). Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England journal of medicine, 371(13), 1189-1197.
Bleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., ... & Goldman, M. (2016). Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. The Lancet, 388(10056), 2115-2127.
FitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., ... & Gilmartin, G. (2016). Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 388(10056), 2128-2141.
延伸閱讀
- 蕭詩如（2009）。免疫球蛋白E抗體阻斷劑在氣喘患者之應用。台灣氣喘衛教學會會刊，(13)，19-22。https://doi.org/10.6669/TAAE.2009.13.19
- Huang, H. Y. (2009). 探討過敏性氣喘的免疫及分子調控機制 [doctoral dissertation, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU.2009.00298
- 曾敬閔（2019）。淺談生物製劑於嚴重型氣喘治療的現況。台北市醫師公會會刊，63(10)，51-53。https://www.airitilibrary.com/Article/Detail?DocID=P20110322001-201910-201910240004-201910240004-51-53
- 蔡肇基（2018）。過敏氣喘疾病免疫療法的最新進展。台灣氣喘衛教學會會刊，(47)，10-13。https://doi.org/10.6669/TAAE.201804_(47).0002
- 葉金水（2007）。抗生素在氣喘急性惡化時的適應症及角色。台灣氣喘衛教學會會刊，(9)，5-7。https://doi.org/10.6669/TAAE.2007.9.5